Clinical trial data shows RAD 101 detects Brain Metastases
Released
Released
Announcement PDF
New clinical trial data highlights RAD 101 (18F-Pivalate) successfully
detects Brain Metastases
•
•
•
Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel
multiparametric imaging methodology (PET-mpMRI) study across 22 patients.
All brain metastases, regardless of whether they were previously treated with radiation
and the tumor of origin, were detected with RAD101, demonstrating a high tumor-tobackground ratio.
A Phase 2b imaging study to evaluate the diagnostic performance of RAD 101 in
individuals with suspected recurrent brain metastases is currently recruiting in the United
States.
Sydney, Australia – 10 February 2025 – Radiopharm Theranostics (ASX:RAD, NASDAQ: RADX
“Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on
developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is
pleased to announce the publication of a novel imaging approach demonstrating proof-of-concept
for the use of RAD 101 for successful detection of brain metastases (both treatment-naïve and
previously treated) from a variety of primary solid tumors.
The clinical study, recently published by Islam et al. in the prestigious European Journal of Nuclear
Medicine and Molecular Imaging 1, reports a novel methodology of detecting brain metastases using
the proprietary radiotracer 18F-RAD101 in a hybrid imaging test that combines Positron Emission
Tomography and Multiparametric Magnetic Resonance Imaging (PET-mpMRI). The study
investigated the imaging characteristics of brain metastases in 12 treatment-naïve (no prior brain
radiotherapy) patients and 10 patients who had previously been treated with brain radiation 2. All
brain metastases, regardless of the tumor of origin, were detected with 18F-RAD101 PET-mpMRI,
with a high tumor-to-background ratio.
RAD 101 is a novel imaging small molecule that targets fatty acid metabolism, which is upregulated
in many solid tumors, including cerebral metastases. Targeting the transport and metabolism of fatty
acid synthase, RAD 101 enables accurate detection of cancer cells, representing a viable target for
the imaging of brain metastases. In October 2022, preliminary positive data from the Imperial
College of London’s Phase 2a imaging trial of RAD 101 in patients with brain metastases showed
significant tumor uptake that was independent from the tumor of origin 3, now confirmed in the
larger study.
Radiopharm’s RAD 101 Phase 2b clinical trial, entitled “An Open-Label, Single Dose, Single Arm,
Multicenter Phase 2b Study to Establish the Imaging Performance of RAD101 Positron Emission
Tomography (PET) in Participants with Suspected Recurrent Brain Metastases from Solid Tumors”, is
1 Islam, S., Inglese, M., Aravind, P. et al. A hybrid [18F]fluoropivalate PET-multiparametric MRI to detect and characterise brain tumour
metastases based on a permissive environment for monocarboxylate transport. Eur J Nucl Med Mol Imaging (2025).
https://doi.org/10.1007/s00259-025-07118-0
2 NCT04807582
3 Poster Presentation - 34th EORTC/AACR/NCI Annual Symposium, Barcelona, Spain, 26-28th October 2022
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
currently open and recruiting in the United States 4. The trial is designed to evaluate the diagnostic
performance of 18F-RAD101 in individuals with suspected recurrent brain metastasis from solid
tumors of different origins.
“Intracranial metastases occur with a frequency four-times higher than primary tumors of the
brain,” said Dr Eric Aboagye, lead inventor of RAD 101, co-author of the publication, Professor of
Cancer Pharmacology & Molecular Imaging at the Imperial College of London, and Director of the
CRUK-EPSRC-MRC-NIHR Comprehensive Cancer Imaging Centre. “With a poor prognosis, there is a
need for improved detection and characterization of these metastases. Our work affirms the current
understanding of the way in which cancers of diverse origin utilise simple short chain fatty acids
compared to glucose and other nutrients in the brain environment, and how to employ this
information to improve detection of metastases in the brain. 18F-RAD101 PET also provides us with
opportunities to delve deeply into therapeutic opportunities.”
“The rising incidence of brain metastases is largely attributed to improved systemic cancer
treatments leading to longer patient survival,” said Riccardo Canevari, CEO and Managing Director of
Radiopharm Theranostics. “Contrast Enhanced MRI is the current standard of care but provides
limited sensitivity for distinguishing disease progression from radiotherapy versus treatment effects.
This is the first clinical study with 18F-RAD101 PET-mpMRI that demonstrates potentially more
sensitive detection of brain metastases compared to current standard of care, offering a strong
potential to improve diagnostic accuracy of suspected recurrent brain metastases.”
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class
platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in
areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021
and on the Nasdaq (RADX) since November 2024. The company has a deep pipeline of highly
differentiated molecules spanning peptides, small molecules and monoclonal antibodies for use in
cancer, in pre-clinical and clinical stages of development. The pipeline has been built based on the
potential to be first-to-market or best-in-class. The clinical program includes one Phase II and three
Phase I trials in a variety of solid tumour cancers including brain, lung, breast and pancreas. Learn
more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman
Paul Hopper.
For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
4 NCT06777433
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Share your feedback
Discover